Effects of desferrithiocin and its derivatives on peripheral iron and striatal dopamine and 5-hydroxytryptamine metabolism in the ferrocene-loaded rat

Biochemical Pharmacology

Volumn 58, Issue 1, 1999, Pages 151-155

  Dexter, David T ^a   Ward, Roberta J ^b   Florence, Anne ^b   Jenner, Peter ^c   Crichton, Robert R ^b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

5 hydroxytryptamine; Brain; Desferrioxamine; Desferrithiocin; Dopamine; Hydroxy pyridones; Iron; Iron chelation

Indexed keywords

CHELATING AGENT; DEFERIPRONE; DEFEROXAMINE; DEFERRIFERRITHIOCIN; DOPAMINE; FERROCENE; HEMOGLOBIN; IRON; SEROTONIN; TRANSFERRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DRUG EFFECT; INTRAPERITONEAL DRUG ADMINISTRATION; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; MALE; MONOAMINE METABOLISM; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN BRAIN LEVEL; TISSUE LEVEL;

ADMINISTRATION, ORAL; ANIMALS; CORPUS STRIATUM; DIHYDROPYRIDINES; DOPAMINE; FERROUS COMPOUNDS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; RATS; RATS, WISTAR; SEROTONIN; THIAZOLES;

EID: 0033168171     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00079-9     Document Type: Article

References (25)

1. Bothwell T.H., Charlton R.W., Cook J.D., Finch C.A. Iron Metabolism in Man. 1979;Blackwell Scientific Publications, Oxford.
2. Finch C.A., Huebers H. Perspectives in iron metabolism. N Engl J Med. 306:1982;1520-1528.
3. Keberle H. The biochemistry of desferrioxamine and its relation to iron metabolism. Ann NY Acad Sci. 119:1964;758-768.
4. 1, an oral iron chelator, in transfusion-dependent thalassemia Indian trial . Br J Haematol. 82:1992;460-466.
5. 1) in thalassemia major. Blood. 80:1992;593-599.
6. 1, CP20), in rat brain in vivo. Biochem Pharmacol. 45:1993;2417-2424.
7. Ward R.J., Dexter D.T., Florence A., Aouad F., Hider R., Jenner P., Crichton R.R. Brain iron in the ferrocene-loaded rat Its chelation and influence on dopamine metabolism . Biochem Pharmacol. 49:1995;1821-1826.
8. Kontoghiorghes G.J. Oral iron chelation is here. Br Med J. 303:1991;1279-1280.
9. McCann U.D., Penetar D.M., Belenky G. Acute dystonic reaction in normal humans caused by catecholamine depletion. Clin Neuropharmacol. 13:1990;565-568.
10. Engelman K., Horowitz D., Jequier E., Sjoerdsma A. Biochemical and pharmacologic effects of alpha-methyl-para-tyrosine in man. J Clin Invest. 47:1968;577-593.
11. Naegeli H.U., Zahner H. Ferrithiocin. Helv Chim Acta. 63:1980;1400-1406.
12. Peter H.H. The present state of iron-chelation therapy. Aksoy M., Birdwood G.F.B., Hypertransfusion and Iron Chelation in Thalassaemia. 1985;69-81 Hans Huber, Berne, Stuttgart, Toronto.
13. Longueville A., Crichton R.R. An animal model of iron overload and its application to study hepatic ferritin iron mobilization by chelators. Biochem Pharmacol. 35:1986;3669-3678.
14. Ward R.J., Florence A.L., Baldwin D., Abiaka C., Roland F., Ramsey M.H., Dickinson D.P.E., Peters R.J., Crichton R.R. Biochemical and biophysical studies of the ferrocene-loaded rat. A suitable model of primary haemochromatosis. Eur J Biochem. 202:1991;405-410.
15. Neilsen P., Heinrich H.C. Metabolism of iron from (3,5,5-trimethyl hexanoyl) ferrocene in rats. A dietary model of severe iron overload. Biochem Pharmacol. 45:1993;385-391.
16. Rose S., Nomoto M., Jenner P. Quantification of dopamine and its metabolites by HPLC. Biochem Pharmacol. 38:1989;3677-3681.
17. Florence A., Ward R.J., Peters T.J., Crichton R.R. Studies of in vivo iron mobilization by chelators in the ferrocene-loaded rat. Biochem Pharmacol. 44:1992;1023-1027.
18. Masserano J.M., Vulliet P.R., Tank A.W., Weiner N. The role of tyrosine hydroxylase in the regulation of catecholamine synthesis. Trendelenburg U., Weiner N., Handbook of Experimental Pharmacology Vol. 90/II. 1989;427-469 Springer, Heidelberg.
19. Fujisawa H., Nakata H. Trytophan 5-mono-oxygenase from rat brain stem. Kaufman S., Metabolism of Aromatic Amino Acids and Amines (Methods in Enzymology Vol. 142). 1987;83-87 Academic Press, New York.
20. Taylor R.J., Stubbs C.S., Ellenbogen L. Tyrosine hydroxylase inhibition in vitro and in vivo by chelating agents. Biochem Pharmacol. 18:1969;587-594.
21. Johansen P.A., Wolf W.A., Kuhn D.M. Inhibition of tryptophan hydroxylase by benzerazide and other catechols. Biochem Pharmacol. 41:1991;625-628.
22. Okuno S., Fujisawa H. Conversion of tyrosine hydroxylase to stable and inactive form by the end products. J Neurochem. 57:1991;53-60.
23. De Graw J.I., Cory M., Skinner W.A., Theisen M.C., Mitoma C. Experimentally induced phenylketonuria. Inhibition of phenylalanine hydroxylase. J Med Chem. 10:1967;64-66.
24. Fuller R.W. Inhibition of rat liver tryptophan hydroxylase in vitro. Life Sci. 4:1965;1-6.
25. Jin Y., Baquet A., Florence A., Crichton R.R., Schneider Y.-J. Desferrithiocin and desferrioxamine B Cellular pharmacology and storage iron mobilization . Biochem Pharmacol. 38:1989;3233-3240.